Literature DB >> 22226108

NK cells--from bench to clinic.

William J Murphy1, Peter Parham, Jeffrey S Miller.   

Abstract

After decades of mouse and human research, we now know that natural killer (NK) cells have unique properties including memory. Although initially described as major histocompatibility complex (MHC) unrestricted killers, NK cells have several families of receptors that directly recognize MHC including Ly49 receptors in the mouse and killer immunoglobulin-like receptors (KIR) in humans. The strength of this signal is determined by polymorphisms in NK cell inhibitory receptor genes and their MHC ligands inherited on different chromosomes. Inhibitory receptors protect "self"-expressing normal tissue from being killed by NK cells and protecting against autoimmunity. Therefore, for NK cells to kill and produce cytokines, they must encounter activating receptor ligands in the context of "missing self" that occurs with some viral infections and malignant transformation. The second property of inhibitory receptors is to educate or license NK cells to acquire function. This is best demonstrated in the mouse and in humans by enhanced function on self-inhibitory receptor-expressing NK cells when in a host expressing cognate ligate. In contrast, NK cells without inhibitory receptors or with nonself-inhibitory receptors are relatively hyporesponsive. The basic biology of NK cells in response to cytokines, education, and viruses will translate into strategies to manipulate NK cells for therapeutic purposes.
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22226108      PMCID: PMC3260456          DOI: 10.1016/j.bbmt.2011.10.033

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  29 in total

Review 1.  Early signaling via inhibitory and activating NK receptors.

Authors:  M Bléry; L Olcese; E Vivier
Journal:  Hum Immunol       Date:  2000-01       Impact factor: 2.850

2.  KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression.

Authors:  Sandra Andersson; Cyril Fauriat; Jenny-Ann Malmberg; Hans-Gustaf Ljunggren; Karl-Johan Malmberg
Journal:  Blood       Date:  2009-03-20       Impact factor: 22.113

3.  NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions.

Authors:  Bree Foley; Sarah Cooley; Michael R Verneris; Julie Curtsinger; Xianghua Luo; Edmund K Waller; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Blood       Date:  2011-07-14       Impact factor: 22.113

4.  "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype.

Authors:  R Kiessling; E Klein; H Wigzell
Journal:  Eur J Immunol       Date:  1975-02       Impact factor: 5.532

5.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

6.  Cutting edge: IL-15-independent NK cell response to mouse cytomegalovirus infection.

Authors:  Joseph C Sun; Averil Ma; Lewis L Lanier
Journal:  J Immunol       Date:  2009-07-31       Impact factor: 5.422

7.  Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.

Authors:  Sarah Cooley; Elizabeth Trachtenberg; Tracy L Bergemann; Koy Saeteurn; John Klein; Chap T Le; Steven G E Marsh; Lisbeth A Guethlein; Peter Parham; Jeffrey S Miller; Daniel J Weisdorf
Journal:  Blood       Date:  2008-10-22       Impact factor: 22.113

8.  Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

Authors:  K Kärre; H G Ljunggren; G Piontek; R Kiessling
Journal:  Nature       Date:  1986 Feb 20-26       Impact factor: 49.962

9.  In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells.

Authors:  Megan A Cooper; Jennifer E Bush; Todd A Fehniger; Jeffrey B VanDeusen; Ross E Waite; Yang Liu; Hector L Aguila; Michael A Caligiuri
Journal:  Blood       Date:  2002-07-05       Impact factor: 22.113

10.  Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice.

Authors:  G Cudkowicz; M Bennett
Journal:  J Exp Med       Date:  1971-12-01       Impact factor: 14.307

View more
  38 in total

1.  Functional NK cell repertoires are maintained through IL-2Rα and Fas ligand.

Authors:  Martin Felices; Todd R Lenvik; Dave E M Ankarlo; Bree Foley; Julie Curtsinger; Xianghua Luo; Bruce R Blazar; Stephen K Anderson; Jeffrey S Miller
Journal:  J Immunol       Date:  2014-03-14       Impact factor: 5.422

2.  Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL.

Authors:  Martin Felices; Behiye Kodal; Peter Hinderlie; Michael F Kaminski; Sarah Cooley; Daniel J Weisdorf; Daniel A Vallera; Jeffrey S Miller; Veronika Bachanova
Journal:  Blood Adv       Date:  2019-03-26

Review 3.  microRNA management of NK-cell developmental and functional programs.

Authors:  Jeffrey W Leong; Ryan P Sullivan; Todd A Fehniger
Journal:  Eur J Immunol       Date:  2014-09-16       Impact factor: 5.532

4.  Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases.

Authors:  Timothy J Henrich; Emily Hanhauser; Francisco M Marty; Michael N Sirignano; Sheila Keating; Tzong-Hae Lee; Yvonne P Robles; Benjamin T Davis; Jonathan Z Li; Andrea Heisey; Alison L Hill; Michael P Busch; Philippe Armand; Robert J Soiffer; Marcus Altfeld; Daniel R Kuritzkes
Journal:  Ann Intern Med       Date:  2014-09-02       Impact factor: 25.391

5.  Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.

Authors:  Veronika Bachanova; Dhifaf Sarhan; Todd E DeFor; Sarah Cooley; Angela Panoskaltsis-Mortari; Bruce R Blazar; Julie M Curtsinger; Linda Burns; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Cancer Immunol Immunother       Date:  2017-12-07       Impact factor: 6.968

Review 6.  Mouse models in bone marrow transplantation and adoptive cellular therapy.

Authors:  Caroline Arber; Malcolm K Brenner; Pavan Reddy
Journal:  Semin Hematol       Date:  2013-06-11       Impact factor: 3.851

7.  Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Authors:  Jeffrey W Leong; Julie M Chase; Rizwan Romee; Stephanie E Schneider; Ryan P Sullivan; Megan A Cooper; Todd A Fehniger
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-13       Impact factor: 5.742

8.  Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.

Authors:  Ricardo García-Muñoz; Ascensión López-Díaz-de-Cerio; Jesus Feliu; Angel Panizo; Pilar Giraldo; Mercedes Rodríguez-Calvillo; Carlos Grande; Esther Pena; Mayte Olave; Carlos Panizo; Susana Inogés
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

9.  Allelic variation in KIR2DL3 generates a KIR2DL2-like receptor with increased binding to its HLA-C ligand.

Authors:  William R Frazier; Noriko Steiner; Lihua Hou; Sivanesan Dakshanamurthy; Carolyn Katovich Hurley
Journal:  J Immunol       Date:  2013-05-17       Impact factor: 5.422

10.  Notch signaling at later stages of NK cell development enhances KIR expression and functional maturation.

Authors:  Martin Felices; Dave E M Ankarlo; Todd R Lenvik; Heather H Nelson; Bruce R Blazar; Michael R Verneris; Jeffrey S Miller
Journal:  J Immunol       Date:  2014-08-29       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.